Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial.
Hirai H, Higa M, Morimoto T, Sakuma M, Arasaki O, Nomiyama T, Node K, Ueda S, Shimabukuro M. Hirai H, et al. Among authors: nomiyama t. J Clin Med. 2019 Dec 30;9(1):93. doi: 10.3390/jcm9010093. J Clin Med. 2019. PMID: 31905896 Free PMC article.
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Furuhashi M, et al. Among authors: nomiyama t. Cardiovasc Diabetol. 2020 Jun 15;19(1):89. doi: 10.1186/s12933-020-01061-0. Cardiovasc Diabetol. 2020. PMID: 32539832 Free PMC article. Clinical Trial.
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Furuhashi M, et al. Among authors: nomiyama t. J Atheroscler Thromb. 2022 Jan 1;29(1):24-37. doi: 10.5551/jat.58396. Epub 2020 Dec 18. J Atheroscler Thromb. 2022. PMID: 33342939 Free PMC article. Clinical Trial.
Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial.
Morimoto T, Sakuma I, Sakuma M, Tokushige A, Natsuaki M, Asahi T, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Morimoto T, et al. Among authors: nomiyama t. Sci Rep. 2019 Jun 12;9(1):8537. doi: 10.1038/s41598-019-44885-x. Sci Rep. 2019. PMID: 31189978 Free PMC article. Clinical Trial.
Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial.
Morimoto T, Sakuma I, Sakuma M, Tokushige A, Natsuaki M, Asahi T, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Morimoto T, et al. Among authors: nomiyama t. Sci Rep. 2020 Feb 21;10(1):3548. doi: 10.1038/s41598-020-60644-9. Sci Rep. 2020. PMID: 32080316 Free PMC article.
Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus.
Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Furuhashi M, et al. Among authors: nomiyama t. Front Endocrinol (Lausanne). 2020 Sep 23;11:575557. doi: 10.3389/fendo.2020.575557. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33071982 Free PMC article. Clinical Trial.
237 results